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Placental function in multifetal pregnancies before and
after embryo reduction was investigated by measuring
maternal serum concentrations of pregnancy associated
placental protein-A (PAPP-A) and pregnancy specific p"-l-
glycoprotein (SP-1). Three groups of pregnant women were
studied following assisted reproduction; groups 1 and 2,
were 12 singleton and 12 twin pregnancies respectively, and
group 3 comprised 12 women with multifetal pregnancies
undergoing embryo reduction. PAPP-A and SP-1 were
measured serially at 8-21 weeks gestation. In all pregnan-
cies, maternal serum PAPP-A and SP-1 increased with
gestation. In twin pregnancies the mean concentrations of
SP-1 were significantly higher than in singletons at all
gestations, whereas for PAPP-A, concentrations were sim-
ilar between these groups. In multifetal pregnancies before
embryo reduction, the serum concentrations of both pro-
teins were significantly higher than hi twin pregnancies.
Following reduction, the concentrations of PAPP-A
remained significantly higher than for twins throughout,
whereas the concentrations of SP-1 gradually converged
towards those of twins; by 19 weeks there was no difference
between the means of the two groups. These findings
suggest that circulating concentrations of SP-1 reflect total
placental mass, which is proportional to the number of live
fetuses, whereas the pattern of PAPP-A changes suggests
that this protein is produced by the placenta, decidua and
other tissues.
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Introduction
Pregnancy-specific (J-l-glycoprotein (SP-1) is produced by the
syncytiotrophoblast and is largely secreted into the maternal
circulation, where it is detectable as early as 6 days after
ovulation (Gordon et al., 1977). Unlike SP-1, which is purely
placental in origin, pregnancy associated placental protein A
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(PAPP-A) is both placental and decidual in origin and the
maximum secretory capacity is determined by both sources
(Lin and Halbert, 1976; Schindler et al, 1984; Rosen, 1986).
In the maternal circulation PAPP-A increases progressively
from the seventh to the 40th week of pregnancy, whereas SP-
1 reaches a plateau at around the 35th week, corresponding to
the gestation when there is a diminishing rate of placental
growth (Gordon et al, 1977; Bischof, 1989). Recent studies
also suggest that the concentrations of these proteins may be
altered in pregnancies affected by fetal trisomies (Bersinger
et al, 1994).
The aim of the study was to investigate placental function
in multifetal pregnancies before and after embryo reduction,
by measuring maternal serum PAPP-A and SP-1.
Materials and methods
Three groups of women with pregnancies achieved by assisted
reproduction were studied. Groups 1 and 2 included 12 singleton and
12 twin pregnancies achieved after in-vitro fertilization (TVF); blood
samples were obtained on five occasions between 8 and 21 weeks
gestation. Group 3 comprised 12 women with multifetal pregnancies
(three fetuses, n = 2; four fetuses, n = 5; five fetuses, n = 2; six
fetuses, n = 2; eight fetuses, n = 1). In this group ultrasound-guided
embryo reduction to twins was performed by transabdominal injection
of potassium chloride into the fetal heart. Maternal blood was obtained
from all 12 cases immediately before embryo reduction at 8-11 weeks
and at subsequent visits at 10-12 weeks, 15-17 and 19-21 weeks.
Ultrasound demonstrated complete resorption of the dead fetuses and
their placentas 8—12 weeks after reduction. All patients gave informed
consent to participate in the study.
PAPP-A was measured by double sandwich time-resolved immuno-
fluorometric assay (TR-IFMA) as described previously (Bischof,
1992) with chelated europium as a label and SP-1 was measured by
an enzyme-linked immunosorbent assay (ELISA) method developed
in our laboratory and using commercially available reagents. The
sensitivity of the assay was 0.02 IU/1 and the intra- and inter-assay
variations were 8.2 and 11.6% respectively.
Serum concentrations of PAPP-A and SP-1 were logarithmically
transformed to adjust for heterogeneity of variance and achieve a
Gaussian distribution. The transformed values before and after embryo
reduction were plotted against gestational age for each of the groups,
singletons, twins and higher multiples, to show the trends with
gestation. Grouped linear regression was used to determine whether
a significant difference existed between the slopes of the lines, and
analysis of covariance was performed to determine whether there
was significant separation of the lines. In those cases where the lines
were converging, intersection of the 95% confidence intervals was
calculated to determine the point at which the two confidence intervals
were no longer significantly different Multiple regression analysis
was performed to determine the significance of associations between
the starting number of fetuses and PAPP-A and SP-1 concentrations.
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Figure 1. Individual values and regression lines of maternal serum
pregnancy associated placental protein A (PAPP-A) with gestation
in singleton (•—), twin (•—) and multifetal reduced to twin
( • ) pregnancies.
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Figure 2. Individual values and regression lines of maternal serum
pregnancy specific protein 1 (SP-1) with gestation in singleton
(•—), twin (•—) and multifetal reduced to twin (£3 )
pregnancies.
Results
In singleton, twin and multifetal pregnancies, there were
significant associations with gestation for maternal serum
PAPP-A concentration (Figure 1; r = 0.89, P < 0.0001,
r = 0.72, P < 0.0001 and r = 0.86, P < 0.0001 respectively)
and serum SP-1 concentration (Figure 2; r = 0.79, P < 0.0001,
r = 0.74, P < 0.0001 and r = 0.80, P < 0.0001 respectively).
The concentration of SP-1 in twin pregnancies was significantly
higher than that in singletons at all gestations examined (t =
-5.67, P < 0.0001), whereas for PAPP-A there was no
significant difference between concentrations in singletons and
twins (/ = -1.26, P = 0.10).
In the multifetal pregnancies, the serum PAPP-A and SP-
1 concentrations before and after embryo reduction were
significantly higher than in the singletons and twins (PAPP-
A: t = -4.84, P < 0.0001; t = -3.65, P = 0.0002; SP-1:
t = -14.6, P < 0.0001; / = -9.0, P < 0.0001 respectively).
The original number of fetuses was significantly associated
with the maternal serum concentration of SP-1 (t = 2.16,
P = 0.04; Table I) but not PAPP-A (t = 1.2, P = 0.24;
Table I). Following embryo reduction, maternal serum
PAPP-A concentrations for multifetal pregnancies remained
significantly higher than those for singleton or twin
pregnancies (Figure 1; t = -4.84, P < 0.0001, and t =
-3.65, P < 0.0001 respectively), and the concentration
continued to rise in parallel for all three groups. In contrast,
serum concentrations of SP-1 progressively converged
towards those of non-reduced twins such that by 19 weeks
there was no significant difference between the groups
(Figure 2).
Table L Maternal serum concentrations of SP-1
of gestation by starting number of fetuses
Number
of fetuses
3-4
2
1
n
5
7
12
12
SP-1 concentration
[median (range) mg/1]
51.1
27.6
4.5
1.9
(46.6-6.3)
(21.3-58.5)
(0.7-11.5)
(0.5-9.9)
and PAPP-A al 8-11 weeks
PAPP-A concentration
[median (range) mg/1]
2.14 (1.27-7.12)
0.56 (0.03-4.95)
0.26 (0.06-3.10)
0.32 (0.11-1.80)
SP-1 = pregnancy specific p^-1-glycoprotein; PAPP-A = pregnancy
associated placental protein-A.
Discussion
The finding that in multifetal pregnancies maternal serum SP-
1 concentration increases with the number of fetuses is
compatible with the placental origin of this peptide, as placental
mass is inevitably a major determinant of circulating concentra-
tions (Stabile et al, 1988). PAPP-A concentration is also
higher in multifetal pregnancies than in singleton or twin
pregnancies. However, unlike SP-1, PAPP-A does not increase
in proportion to the number of fetuses, presumably because
this protein is produced by the decidua as well as the placenta
and the maximum secretory capacity of the endometrium is
achieved with twin pregnancy (Lin and Halbert, 1976; Abbas
et al., 1995).
Multifetal pregnancy reduction to twins was associated with
a relative decrease in maternal serum SP-1 concentration to
that of the control twin group (group 2). In this respect, the
pattern of change in SP-1 is similar to that of human chorionic
gonadotrophin (HCG) and suggests that fetal reduction causes
placental death and therefore decline in production of both
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placental products (Johnson et al, 1994a). These findings are
different from those of maternal serum relaxin and a-feto-
protein (a-FP) (Abbas et al, 1994; Johnson et al, 1994b). In
multifetal pregnancies relaxin concentration increases with the
number of fetuses but following reduction to twins, the level
does not change; this is presumably because relaxin is a
product of the corpus luteum whose function is unaffected by
feto-placental death (Johnson et al, 1994b). In the case of a-
FP, embryo reduction was associated with an increase in
maternal serum concentration which persisted for at least 10
weeks before decreasing to twin values; a-FP is stored in fetal
tissues and after fetal death and tissue breakdown it is released
into the amniotic fluid from where it is absorbed into the
maternal circulation (Abbas et al., 1994).
Relative concentrations of maternal serum PAPP-A did not
change significantly following fetal reduction. Unlike SP-1,
which has a half-life of ~30 h and disappears from the
circulation soon after delivery, PAPP-A remains detectable in
the maternal circulation for 4-6 weeks post-partum (Bohn,
1974; Lin et al, 1976). This long half-life of PAPP-A could
offer an explanation for the persistence of high concentrations
following fetal reduction. Alternatively, PAPP-A is produced
not only by the placenta, but by decidua and additional tissues,
with the controlling mechanism set early in the pregnancy.
This explanation is probably more likely in respect of the
continued rise in PAPP-A values in parallel to those of non-
reduced twins.
In multifetal pregnancies undergoing embryo reduction there
is a procedure-related risk of spontaneous abortion, which
usually occurs within 2 weeks of the intervention and is about
1-2%. However, there is a persisting risk of spontaneous
abortion or severe preterm delivery which is much higher than
in spontaneously conceived twins. For example the prevalence
of preterm delivery before 32 weeks of gestation is about 1%
in singleton pregnancies, 10% in twins, 30% in triplets (US
Government, 1993) and 15% in multifetal pregnancies reduced
to twins (Evans et al, 1994). It is possible that the persistence
of risk of miscarriage for several weeks after the procedure is
due to the release of cytokines and stimulation of prostaglandins
in response to the resorbing placental tissue of the dead fetuses.
The slow relative decline in maternal SP-1 concentrations
following embryo reduction presumably reflects the gradual
degeneration of placental tissue and therefore, the persistence
for several weeks of the stimulus for cytokine production.
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